Skip to main content
78°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Entrada Therapeutics, Inc.
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 24, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 24, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 16, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 12, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
August 01, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
April 04, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
March 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
February 09, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
January 09, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
December 19, 2022
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 22, 2022
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Appoints Biotech Industry Leader Mary Thistle to Its Board of Directors
May 04, 2021
From
Entrada Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.